Snubbed, Miraculins Withdraws Offer to Acquire IBEX | GenomeWeb
NEW YORK (GenomeWeb News) — Canadian biomarker company Miraculins has withdrawn its offer to acquire diagnostics developer IBEX technologies.
 
In mid-November Winnipeg-based Miraculins made an unsolicited offer to acquire IBEX through a stock deal that would exchange one common Miraculins share for five shares in IBEX.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.